Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.27.4 (
ribonuclease
)
6,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To characterize the role of hyaluronidase (Hyl) of Streptococcus suis serotype 2 (S. suis 2), the hylA gene that encodes Hyl was cloned, expressed and purified. A murine brain cDNA library was used to screen for interacting proteins of Hyl. Employing the yeast two-hybrid system, a novel murine
ribonuclease
, angiogenin inhibitor 1 (AI1), which shares 93% homology with porcine AI1, was shown to interact with Hyl in yeast. Through co-immunoprecipitation assays, the interaction between AI1 and Hyl was further confirmed. Transcription and translation products of the identified cDNA were detected in both normal cells and S. suis 2-infected cells. AI1 was found to localize mainly in the cytoplasm of 293T cells. These results suggested that the identified protein AI1 might be involved in the pathogenesis of
meningitis
through interaction with Hyl of S. suis 2.
...
PMID:Identification of a novel angiogenin inhibitor 1 and its association with hyaluronidase of Streptococcus suis serotype 2. 2030 45
Background:
Streptococcus pneumoniae
colonize the human nasopharynx in the form of biofilms. The biofilms act as bacterial reservoirs and planktonic bacteria from these biofilms can migrate to other sterile anatomical sites to cause pneumonia, otitis media (OM), bacteremia and
meningitis
. Human amniotic membrane contains numerous growth factors and antimicrobial activity; however, these have not been studied in detail. In this study, we prepared amniotic membrane extract and chorionic membrane extract (AME/CME) and evaluated their antibacterial and antibiofilm activities against
S. pneumoniae
using an
in vitro
biofilm model and
in vivo
OM rat model.
Materials and Methods:
The AME/CME were prepared and protein was quantified using DC
TM
(detergent compatible) method. The minimum inhibitory concentrations were determined using broth dilution method, and the synergistic effect of AME/CME with Penicillin-streptomycin was detected checkerboard. The
in vitro
biofilm and
in vivo
colonization of
S. pneumoniae
were studied using microtiter plate assay and OM rat model, respectively. The AME/CME-treated biofilms were examined using scanning electron microscope and confocal microscopy. To examine the constituents of AME/CME, we determined the proteins and peptides of AME/CME using tandem mass tag-based quantitative mass spectrometry.
Results:
AME/CME treatment significantly (
p
< 0.05) inhibited
S. pneumoniae
growth in planktonic form and in biofilms. Combined application of AME/CME and Penicillin-streptomycin solution had a synergistic effect against
S. pneumoniae.
Biofilms grown with AME/CME were thin, scattered, and unorganized. AME/CME effectively eradicated pre-established pneumococci biofilms and has a bactericidal effect. AME treatment significantly (
p
< 0.05) reduced bacterial colonization in the rat middle ear. The proteomics analysis revealed that the AME/CME contains hydrolase,
ribonuclease
, protease, and other antimicrobial proteins and peptides.
Conclusion:
AME/CME inhibits
S. pneumoniae
growth in the planktonic and biofilm states via its antimicrobial proteins and peptides. AME/CME are non-cytotoxic, natural human product; therefore, they may be used alone or with antibiotics to treat
S. pneumoniae
infections.
...
PMID:Antimicrobial and Antibiofilm Effects of Human Amniotic/Chorionic Membrane Extract on
Streptococcus pneumoniae
. 2908 28
